Niagen Bioscience (NAGE) Current Leases (2011 - 2026)
Niagen Bioscience (NAGE) posted quarterly Current Leases of $1.0 million for Q1 2026, up 11366.67% year-over-year from N/an in Q1 2025, and up 2.99% quarter-over-quarter from $1.0 million in Q4 2025.
Niagen Bioscience (NAGE) Current Leases (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Current Leases for 14 consecutive years, with $1.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Leases rose 11366.67% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at $1.0 million (up 11366.67% YoY), while the FY2025 annual figure was $1.0 million, up 8250.0% from the prior year.
- Current Leases grew to $1.0 million in Q1 2026 per NAGE's latest filing, from $1.0 million in the prior quarter.
- Across five years, Current Leases topped out at $1.0 million in Q1 2026 and bottomed at $9000.0 in Q1 2025.
- Historically, Current Leases has averaged $369294.1 across 5 years, with a median of $17000.0 in 2022.
- Annual changes were most pronounced in 2024 — Current Leases tumbled 98.59% — and 2026, when it jumped 11366.67%.
- Niagen Bioscience's Current Leases stood at $16000.0 in 2022, then plunged by 31.25% to $11000.0 in 2023, then increased by 9.09% to $12000.0 in 2024, then soared by 8250.0% to $1.0 million in 2025, then grew by 2.99% to $1.0 million in 2026.
- Business Quant data shows NAGE's Current Leases at $1.0 million in Q1 2026, $1.0 million in Q4 2025, and $976000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn | 917,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 917,000.00 |
| Mar 31, 2026 | 1.03 Mn |
| Dec 31, 2025 | 1.00 Mn |
| Sep 30, 2025 | 976,000.00 |
| Jun 30, 2025 | 957,000.00 |
| Mar 31, 2025 | 9,000.00 |
| Dec 31, 2024 | 12,000.00 |
| Sep 30, 2024 | 12,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Dec 31, 2023 | 11,000.00 |
| Sep 30, 2023 | 854,000.00 |
| Jun 30, 2023 | 10,000.00 |
| Mar 31, 2023 | 17,000.00 |
| Dec 31, 2022 | 16,000.00 |
| Sep 30, 2022 | 684,000.00 |
| Jun 30, 2022 | 646,000.00 |
| Mar 31, 2022 | 17,000.00 |
| Dec 31, 2021 | 528,000.00 |
| Sep 30, 2021 | 447,000.00 |